Navigation Links
Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
Date:12/3/2007

SOUTH SAN FRANCISCO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today announced the appointment of Lesley A. Stolz, Ph.D., to the position of Vice President, Corporate and Business Development. Dr. Stolz will be responsible for overseeing the company's partnering and collaboration activities, reporting directly to Eric Bjerkholt, Senior Vice President, Corporate Development and Finance.

"We are pleased to welcome Lesley to the Sunesis team. Her proven track record and diverse experience in managing all aspects of partnering, in-licensing, intellectual property transfers and M&A activities will provide valuable insights to all of our strategic business development initiatives," said Daniel Swisher, Chief Executive Officer and President of Sunesis.

Dr. Stolz joins Sunesis with more than a decade of biotechnology industry experience. Most recently, she served as Senior Director, Business Development for Aerovance, Inc. where she led efforts to partner the company's Phase 2 asset for uncontrolled asthma. Dr. Stolz was Senior Director, Business Development for GPC Biotech AG of Germany from 2002 to 2006 where she co-led the acquisition of Axxima Pharmaceuticals. While there, she was also responsible for the discovery, evaluation and execution of GPC Biotech's in-licensing activities and helped to set business development and merger and acquisition strategies. From 2001 to 2002, Dr. Stolz served as Director, Business Development for Cell Genesys, Inc. with responsibility for identifying and negotiating partnerships for the company's cancer therapy research and development programs. Dr. Stolz received her Ph.D. and M.S. degrees from the University of Rochester and a B.S. from the University of Virginia. She conducted postdoctoral research at Harvard Medical School's Department of Biochemistry and Molecular Pharmacology.

Option Award Disclosure

The Compensation Committee of the company's Board of Directors approved an employment commencement inducement grant to Dr. Stolz of a non-qualified stock option to purchase 60,000 shares of Sunesis common stock, effective November 30, 2007. Pursuant to Nasdaq Marketplace Rule 4350 (i)(1)(A)(iv), this option award was granted without shareholder approval under Sunesis' 2006 Employment Commencement Incentive Plan. Nasdaq rules require public announcement of option grants made under this type of plan. The options were granted at an exercise price equal to the fair market value of the company's common stock at the close of the trading day on the grant date. The options have a ten-year term, and, subject to the terms and conditions of the company's 2006 Employment Commencement Incentive Plan, vest over four years as follows: 25 percent of the shares will vest on the one year anniversary of the grant date, and the remaining 75 percent will vest in 36 equal monthly increments during each of the second, third and fourth years thereafter.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):